Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) just unveiled an announcement.
Clarity Pharmaceuticals Ltd has announced the quotation of 20,721 fully paid ordinary securities on the ASX, effective August 4, 2025. This move is part of the company’s ongoing efforts to enhance its market presence and provide liquidity to its stakeholders, reflecting its strategic focus on expanding its operational capabilities and market reach.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$8.20 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on the development and commercialization of radiopharmaceuticals for the treatment of serious diseases. The company is listed on the Australian Securities Exchange (ASX) under the issuer code CU6.
Average Trading Volume: 3,091,715
Technical Sentiment Signal: Buy
Current Market Cap: A$1.66B
For detailed information about CU6 stock, go to TipRanks’ Stock Analysis page.